CEO Bernard Coulie was paid $5,462,901 in fiscal year 2025, ↓ down 17.4% from fiscal year 2024, the 45th percentile of its disclosed peer group (SEC filing 0001746473-26-000076 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,462,901 ↓ Bernard Coulie total, FY2025 | 45th CEO pay percentile vs peers | — CEO-to-median pay ratio | 51.19% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
PLRX's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bernard Coulie | $682,000 | $0 | $1,810,250 | $2,713,750 | $204,600 | $0 | $52,301 | $5,462,901 |
| President, Chief Executive Officer and Director | ||||||||
| Eric Lefebvre | 571,861 | 215,617 | 508,541 | 762,355 | 0 | 0 | 666,486 | 2,724,860 |
| Former Chief Medical Officer | ||||||||
| Keith Cummings | 503,876 | 201,550 | 631,081 | 946,055 | 100,775 | 0 | 14,000 | 2,397,337 |
| Chief Financial Officer | ||||||||
| Minnie Kuo | 470,696 | 188,279 | 307,464 | 460,920 | 103,553 | 0 | 11,942 | 1,542,854 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bernard Coulie | $5,462,901 | $6,614,704 | $11,165,999 | ↓ −1,151,803 |
| Eric Lefebvre | 2,724,860 | 2,615,618 | 4,687,061 | ↑ +109,242 |
| Keith Cummings | 2,397,337 | 3,099,874 | 4,438,908 | ↓ −702,537 |
| Minnie Kuo | 1,542,854 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read PLIANT THERAPEUTICS, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PLRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the PLIANT THERAPEUTICS, INC. Peer Teardown Report
$5,462,901 Bernard Coulie total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 2, 2026 · Source: 0001746473-26-000076 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for PLRX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order PLRX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name PLRX as a peer is temporarily unavailable — recheck shortly.
Get the PLIANT THERAPEUTICS, INC. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Darren Cline | Independent Director | $90,100 |
| David Pyott | Independent Director | $90,100 |
| Gayle Crowell | Independent Director | $95,100 |
| Hoyoung Huh | Independent Director | $112,600 |
| John Curnutte | Independent Director | $82,600 |
| Katharine Knobil | Independent Director | $95,100 |
| Smital Shah | Former director (through FY2025) | $21,566 |
| Steve Krognes | Independent Director | $95,100 |
| Suzanne Bruhn | Independent Director | $87,600 |
| Thomas McCourt | Independent Director | $90,100 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thomas McCourt | Director | 2026-06-11 | A | 70,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Darren Cline | Director | 2026-06-11 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hoyoung Huh | Director | 2026-06-11 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Curnutte | Director | 2026-06-11 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steve Krognes | Director | 2026-06-11 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gayle Crowell | Director | 2026-06-11 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | Director | 2026-07-09 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Flavia Borellini | Director | 2026-07-09 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Raben | Chief Medical Officer | 2026-10-01 | A | 575,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bernard Coulie | OTHER | — | — | — | — | — | $1,810,250 |
| Minnie Kuo | OTHER | — | — | — | — | — | 307,464 |
| Keith Cummings | OTHER | — | — | — | — | — | 631,081 |
| Eric Lefebvre | OTHER | — | — | — | — | — | 508,541 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Eric Lefebvre | Option | 70,378 | 11.14 | — |
| Bernard Coulie | Option | 133,490 | 17.44 | — |
| Keith Cummings | RSU | 18,000 | — | 21,960 |
| Bernard Coulie | RSU | 162,500 | — | 198,250 |
| Bernard Coulie | RSU | 85,433 | — | 104,228 |
| Keith Cummings | RSU | 56,650 | — | 69,113 |
| Bernard Coulie | RSU | 48,766 | — | 59,495 |
| Eric Lefebvre | RSU | 45,650 | — | 55,693 |
| Eric Lefebvre | Option | 21,667 | 34.65 | — |
| Keith Cummings | RSU | 36,833 | — | 44,936 |
| Eric Lefebvre | Option | 44,688 | 17.44 | — |
| Eric Lefebvre | RSU | 28,600 | — | 34,892 |
| Minnie Kuo | RSU | 27,600 | — | 33,672 |
| Eric Lefebvre | RSU | 19,000 | — | 23,180 |
| Minnie Kuo | RSU | 13,333 | — | 16,266 |
| Bernard Coulie | Option | 9,167 | 11.86 | — |
| Bernard Coulie | Option | 55,873 | 34.65 | — |
| Bernard Coulie | Option | 250,521 | 11.14 | — |
| Keith Cummings | Option | 2,584 | 11.86 | — |
| Keith Cummings | Option | 20,638 | 34.65 | — |
| Keith Cummings | Option | 57,553 | 17.44 | — |
| Keith Cummings | Option | 87,336 | 11.14 | — |
| Minnie Kuo | Option | 65,625 | 16.18 | — |
| Minnie Kuo | Option | 20,834 | 17.44 | — |
| Minnie Kuo | Option | 42,550 | 11.14 | — |
| Eric Lefebvre | Option | 2,917 | 11.86 | — |
The company's compensation philosophy is market-based, designed to align executive interests with stockholders and long-term success. It emphasizes a pay-for-performance culture, allocating a significant portion of total target compensation to incentive-based opportunities and variable compensation.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 15,282,788 | 14,572,455 | 776,605 | 51.19% | Passed |
| 2025 | 2025-06-05 | 30,037,373 | 8,937,835 | 910,949 | 77.07% | Passed |
| 2024 | 2024-06-13 | 23,479,353 | 28,329,655 | 10,277 | 45.32% | Failed |
| 2023 | 2023-06-07 | 47,994,590 | 1,379,942 | 36,200 | 97.21% | Passed |
| 2022 | 2022-06-16 | 27,888,784 | 111,574 | 8,625 | 99.6% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 51.19%a |
| 2025 | 2025-06-05 | 77.07%b |
| 2024 | 2024-06-13 | 45.32%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Hoyoung HuhIndependent · Compensation | $77,500 | $0 | $35,100 | — | $0 | $112,600 |
| Gayle CrowellIndependent · Audit · Nominating And Corporate Governance (Chair) | 60,000 | 0 | 35,100 | — | 0 | 95,100 |
| Katharine KnobilIndependent · Nominating And Corporate Governance · Research And Development | 60,000 | 0 | 35,100 | — | 0 | 95,100 |
| Steve KrognesIndependent · Audit (Chair) | 60,000 | 0 | 35,100 | — | 0 | 95,100 |
| Thomas McCourtIndependent · Compensation · Research And Development | 55,000 | 0 | 35,100 | — | 0 | 90,100 |
| David PyottIndependent · Audit · Nominating And Corporate Governance | 55,000 | 0 | 35,100 | — | 0 | 90,100 |
| Darren ClineIndependent · Compensation (Chair) · Nominating And Corporate Governance | 55,000 | 0 | 35,100 | — | 0 | 90,100 |
| Suzanne BruhnIndependent · Compensation · Nominating And Corporate Governance | 52,500 | 0 | 35,100 | — | 0 | 87,600 |
| John CurnutteIndependent · Research And Development | 47,500 | 0 | 35,100 | — | 0 | 82,600 |
| Smital ShahIndependent · Departed during FY | 21,566 | 0 | 0 | — | 0 | 21,566 |
| Bernard CoulieEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $544,066 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $544,066 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies PLIANT THERAPEUTICS, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including PLIANT THERAPEUTICS, INC..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 3 | Crinetics Pharmaceuticals | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 4 | Akero Therapeutics | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 5 | Disc Medicine | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 6 | IDEAYA Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 7 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 8 | Structure Therapeutics, Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 9 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 10 | Day One Biopharmaceuticals | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 11 | iTeos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 12 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 13 | PLIANT THERAPEUTICS, INC. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 14 | KalVista Pharmaceuticals | 2025 | Benjamin Palleiko | 477,202 | 3,731,160 | 0 | 0 | 5,094,999 |
| 15 | Kura Oncology | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 16 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 17 | Rocket Pharmaceuticals | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 18 | IGM Biosciences | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 19 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 20 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 21 | 4D Molecular Therapeutics | 2025 | David Kirn | 667,252 | 0 | 822,750 | 560,597 | 2,051,343 |
| 22 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 23 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| PLIANT THERAPEUTICS, INC. | not disclosed | Options 67 · RSU 33 | not disclosed | Alpine Rewards |
| 4D Molecular Therapeutics | 140% | Options 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Akero Therapeutics | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Crinetics Pharmaceuticals | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Day One Biopharmaceuticals | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Disc Medicine | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| IDEAYA Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| IGM Biosciences | not disclosed | not disclosed | not disclosed | Aon |
| iTeos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| KalVista Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kura Oncology | 150% | not disclosed | No | Alpine Rewards |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Rocket Pharmaceuticals | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Scholar Rock | not disclosed | not disclosed | No | Pay Governance |
| Structure Therapeutics, Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Bernard Coulie | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Executive Compensation”. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 2 | Section 01, Eric Lefebvre | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Executive Compensation”. As printed: 2,724,860. Filing ↗machine: r7 · c48 · span 449046–449055 |
| 3 | Section 01, Keith Cummings | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Executive Compensation”. As printed: 2,397,337. Filing ↗machine: r4 · c48 · span 441769–441778 |
| 4 | Section 01, Minnie Kuo | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Executive Compensation”. As printed: 1,542,854. Filing ↗machine: r6 · c48 · span 446567–446576 |
| 5 | Section 03, Bernard Coulie OTHER | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t34 · r2 · c8 · span 435543–435552 |
| 6 | Section 03, Minnie Kuo OTHER | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t34 · r6 · c8 · span 445384–445391 |
| 7 | Section 03, Keith Cummings OTHER | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t34 · r4 · c8 · span 440774–440781 |
| 8 | Section 03, Eric Lefebvre OTHER | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t34 · r7 · c8 · span 448050–448057 |
| 9 | Section 07, pay ratio | 10-K | 2026-03-11 | 0001746473-26-000037 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 10 | Section 08, Hoyoung Huh | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 112,600. Filing ↗machine: span 230087–230317 |
| 11 | Section 08, Gayle Crowell | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 95,100. Filing ↗machine: span 224703–224932 |
| 12 | Section 08, Katharine Knobil | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 95,100. Filing ↗machine: span 231428–231657 |
| 13 | Section 08, Steve Krognes | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 95,100. Filing ↗machine: span 232773–233002 |
| 14 | Section 08, Thomas McCourt | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 90,100. Filing ↗machine: span 228738–228967 |
| 15 | Section 08, David Pyott | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 90,100. Filing ↗machine: span 234124–234353 |
| 16 | Section 08, Darren Cline | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 90,100. Filing ↗machine: span 227399–227628 |
| 17 | Section 08, Suzanne Bruhn | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 87,600. Filing ↗machine: span 223345–223600 |
| 18 | Section 08, John Curnutte | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 82,600. Filing ↗machine: span 226054–226283 |
| 19 | Section 08, Smital Shah | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 21,566. Filing ↗machine: span 234865–235094 |
| 20 | Section 08, Bernard Coulie | DEF 14A | 2026-04-22 | 0001746473-26-000076 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 02, Thomas McCourt 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Darren Cline 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Hoyoung Huh 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, John Curnutte 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Steve Krognes 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Gayle Crowell 2026-06-11 | Form 4 | 2026-06-12 | 0001746473-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Robert Iannone 2026-07-09 | Form 4 | 2026-07-13 | 0001737329-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Flavia Borellini 2026-07-09 | Form 4 | 2026-07-13 | 0001867426-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, David Raben 2026-10-01 | Form 4 | 2026-10-02 | 0001746473-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001746473-26-000092 | Item 5.07 · say-on-pay result. As reported: 51.19% (votes for as printed: 15,282,788). Filing ↗ |
| 31 | Section 06, 2025 vote | Form 8-K | 2025-06-09 | 0001746473-25-000105 | Item 5.07 · say-on-pay result. As reported: 77.07% (votes for as printed: 30,037,373). Filing ↗ |
| 32 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001746473-24-000084 | Item 5.07 · say-on-pay result. As reported: 45.32% (votes for as printed: 23,479,353). Filing ↗ |
| 33 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 34 | Section 09b board cost (computed) | Computed | — | — | Cash 544,066 + equity 0 + all other 0 = 544,066, summed across the director compensation table rows.machine: formula: Σ = 544,066 |
| 35 | Scholar Rock, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046917 | CEO total compensation as printed in Scholar Rock's own proxy. As printed: 33,300,927. Filing ↗machine: r1 · c47 · span 363867–363877 |
| 36 | Protagonist Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050429 | CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. Filing ↗machine: r1 · c47 · span 613195–613205 |
| 37 | Crinetics Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals's own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 38 | Akero Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-28 | 0000950170-25-058964 | CEO total compensation as printed in Akero Therapeutics's own proxy. As printed: 10,465,855. Filing ↗machine: t13 · r2 · c14 · span 492349–492359 |
| 39 | Disc Medicine, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187646 | CEO total compensation as printed in Disc Medicine's own proxy. As printed: 9,986,626. Filing ↗machine: r2 · c29 · span 696477–696486 |
| 40 | IDEAYA Biosciences, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191501 | CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. Filing ↗machine: r2 · c14 · span 627310–627319 |
| 41 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 42 | Structure Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047740 | CEO total compensation as printed in Structure Therapeutics, Inc.'s own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 43 | Viridian Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160344 | CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778 |
| 44 | Day One Biopharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals's own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 45 | iTeos Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-057666 | CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
| 46 | Replimune Group, Section 10b CEO total | DEF 14A | 2026-07-29 | 0001104659-26-087650 | CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774 |
| 47 | PLIANT THERAPEUTICS, INC. (subject), Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in PLIANT THERAPEUTICS, INC.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 48 | KalVista Pharmaceuticals, Section 10b CEO total | 10-K/A | 2026-04-30 | 0001193125-26-197556 | CEO total compensation as printed in KalVista Pharmaceuticals's own proxy. As printed: 5,094,999. Filing ↗ |
| 49 | Kura Oncology, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151335 | CEO total compensation as printed in Kura Oncology's own proxy. As printed: 4,735,016. Filing ↗machine: span 1018180–1018189 |
| 50 | Erasca, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187361 | CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533 |
| 51 | Rocket Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013335 | CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. Filing ↗machine: r2 · c24 · span 348766–348775 |
| 52 | IGM Biosciences, Section 10b CEO total | DEF 14A | 2024-04-26 | 0000950170-24-049091 | CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |
| 53 | Olema Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191956 | CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. Filing ↗machine: t29 · r5 · c16 · span 612371–612380 |
| 54 | Keros Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046791 | CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. Filing ↗machine: r1 · c41 · span 627980–627989 |
| 55 | 4D Molecular Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017427 | CEO total compensation as printed in 4D Molecular Therapeutics's own proxy. As printed: 2,051,343. Filing ↗machine: r2 · c21 · span 356185–356194 |
| 56 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 57 | Arcturus Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193805-26-000507 | CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919 |
| 58 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 59 | Section 10a, Disc Medicine reciprocity | DEF 14A | — | 0001193125-26-187646 | Disc Medicine's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 60 | Section 10a, Scholar Rock reciprocity | DEF 14A | — | 0001104659-26-046917 | Scholar Rock's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 61 | Section 10a, Keros Therapeutics reciprocity | DEF 14A | — | 0001104659-26-046791 | Keros Therapeutics names PLIANT THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 62 | Section 10a, Olema Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-191956 | Olema Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 63 | Section 10a, IDEAYA Biosciences reciprocity | DEF 14A | — | 0001193125-26-191501 | IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 64 | Section 10a, Arcturus Therapeutics reciprocity | DEF 14A | — | 0001193805-26-000507 | Arcturus Therapeutics's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 65 | Section 10a, Structure Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-047740 | Structure Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 66 | Section 10a, Viridian Therapeutics reciprocity | DEF 14A | — | 0001193125-26-160344 | Viridian Therapeutics names PLIANT THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 67 | Section 10a, Crinetics Pharmaceuticals reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 68 | Section 10a, Protagonist Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050429 | Protagonist Therapeutics's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 69 | Section 10a, Kura Oncology reciprocity | DEF 14A | — | 0001193125-26-151335 | Kura Oncology's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 70 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 71 | Section 10a, Rocket Pharmaceuticals reciprocity | DEF 14A | — | 0001140361-25-016656 | Rocket Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 72 | Section 10a, Akero Therapeutics reciprocity | DEF 14A | — | 0000950170-25-058964 | Akero Therapeutics's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 73 | Section 10a, Day One Biopharmaceuticals reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
| 74 | Section 10a, IGM Biosciences reciprocity | DEF 14A | — | 0000950170-24-049091 | IGM Biosciences's most recent proxy was read; its disclosed peer group does not include PLIANT THERAPEUTICS, INC.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the PLIANT THERAPEUTICS, INC. Executive Compensation Report
$1,500